Recommended Phase II Dose
Preclinical
Recommended Phase II Dose is one of 6 therapeutic programs targeting Melanoma (Skin Cancer). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Melanoma (skin Cancer)
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Yervoy
Bristol-Myers SquibbPhase 2
Truqap
AstraZenecaPreclinical
Faslodex
FFresenius Kabi USA, LLC
Preclinical
AMXT 1501 Dicaprate
AAminex Therapeutics, Inc.
Preclinical
Recommended Phase II Dose
IInstitute of Cancer Research, United Kingdom
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Recommended Phase II Dose. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]